Ginwa Enterprise Group Inc
SSE:600080
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ginwa Enterprise Group Inc
Income from Continuing Operations
Ginwa Enterprise Group Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ginwa Enterprise Group Inc
SSE:600080
|
Income from Continuing Operations
¥77.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
13%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥5.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥8.1B
|
CAGR 3-Years
28%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥5.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Income from Continuing Operations
¥6.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
33%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
244%
|
CAGR 10-Years
N/A
|
|
Ginwa Enterprise Group Inc
Glance View
Ginwa Enterprise (Group) Inc. engages in the manufacture and distribution of pharmaceuticals. The company is headquartered in Xi'An, Shaanxi and currently employs 607 full-time employees. The firm's main product is jintiange capsules, used for treatment of osteoporosis. The firm provides products in various forms, including tablets, oral solutions, capsules and others. In addition, the Company involves in the provision of hotel services and operation of rental business. Through its subsidiaries, the Company is involved in hotel operation business, wholesale and retail of pharmaceuticals and medical devices, as well as television drama production businesses and others.
See Also
What is Ginwa Enterprise Group Inc's Income from Continuing Operations?
Income from Continuing Operations
77.1m
CNY
Based on the financial report for Sep 30, 2025, Ginwa Enterprise Group Inc's Income from Continuing Operations amounts to 77.1m CNY.
What is Ginwa Enterprise Group Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
13%
